SCHEMBL6718795

SCHEMBL6718795

CC(C)c1ccc(NC(=O)C(N)c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRHBP P24387 1/20 0.64
▸ CRHR2 Q13324 1/20 0.64
▸ PTPN1 P18031 1/20 0.58
▸ PTPN6 P29350 1/20 0.58
▸ PTPN11 Q06124 1/20 0.58
▸ TAAR1 Q96RJ0 1/20 0.55
▸ ALDH1A1 P00352 4/20 0.54
▸ TSHR P16473 1/20 0.54
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ KIF11 P52732 1/20 0.53
▸ RAB9A P51151 2/20 0.52
▸ EGFR P00533 1/20 0.52
▸ MAPT P10636 2/20 0.52
▸ ROCK2 O75116 1/20 0.52
▸ ROCK1 Q13464 1/20 0.52
▸ TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL6713928 0.94 CRHBP (0.58) CRHBPCRHR2PTPN1PTPN6PTPN11
SCHEMBL19074543 0.86 POLB (0.66) TAAR1ALDH1A1TSHRRAB9AMAPT
SCHEMBL4982071 0.86 POLB (0.66) TAAR1ALDH1A1TSHRRAB9AMAPT
SCHEMBL3836963 0.85 ROCK2 (0.58) TAAR1ALDH1A1RAB9AROCK2ROCK1
SCHEMBL6723553 0.85 ROCK2 (0.58) TAAR1ALDH1A1RAB9AROCK2ROCK1
SCHEMBL6717109 0.85 ALDH1A1 (0.63) TAAR1ALDH1A1RAB9AMAPTROCK2
SCHEMBL6717100 0.85 ALDH1A1 (0.63) TAAR1ALDH1A1RAB9AMAPTROCK2
SCHEMBL23611208 0.85 ROCK2 (0.56) CRHBPCRHR2TAAR1ALDH1A1MAPT
SCHEMBL23611205 0.85 ROCK2 (0.56) CRHBPCRHR2TAAR1ALDH1A1MAPT
Dimethylamine SCHEMBL6726772 0.85 POLB (0.59) TAAR1ALDH1A1MAPTROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 — — US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 — — WO disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 CRHBP 1808/4885CRHR2 1096/4885PTPN1 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback